{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:03:14Z","timestamp":1792461794239,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2021\/05\/X\/NZ7\/00353"],"award-info":[{"award-number":["2021\/05\/X\/NZ7\/00353"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>For therapeutic drug monitoring (TDM) of mycophenolic acid (MPA), which is frequently proposed, saliva might be a suitable and easy-to-obtain biological matrix. The study aimed to validate an HPLC method with fluorescence detection for determining mycophenolic acid in saliva (sMPA) in children with nephrotic syndrome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The mobile phase was composed of methanol and tetrabutylammonium bromide with disodium hydrogen phosphate (pH 8.5) at a 48:52 ratio. To prepare the saliva samples, 100 \u00b5L of saliva, 50 \u00b5L of calibration standards, and 50 \u00b5L of levofloxacin (used as an internal standard) were mixed and evaporated to dryness at 45\u00a0\u00b0C for 2\u00a0h. The resulting dry extract was reconstituted in the mobile phase and injected into the HPLC system after centrifugation. Saliva samples from study participants were collected using Salivette<jats:sup>\u00ae<\/jats:sup> devices.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The method was linear within the range of 5\u20132000\u00a0ng\/mL, was selective with no carry-over effect and met the acceptance criteria for within-run and between-run accuracy and precision. Saliva samples can be stored for up to 2\u00a0h at room temperature, for up to 4\u00a0h at 4\u00a0\u00b0C, and for up to 6\u00a0months at \u2212\u00a080\u00a0\u00b0C. MPA was stable in saliva after three freeze\u2013thaw cycles, in dry extract for 20\u00a0h at 4\u00a0\u00b0C, and for 4\u00a0h in the autosampler at room temperature. MPA recovery from Salivette<jats:sup>\u00ae<\/jats:sup> cotton swabs was within the range of 94\u2013105%. The sMPA concentrations in the two children with nephrotic syndrome who were treated with mycophenolate mofetil were within 5\u2013112\u00a0ng\/mL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The sMPA determination method is specific, selective, and meets the validation requirements for analytic methods. It may be used in children with nephrotic syndrome; however further studies are required to investigate focusing on sMPA and the correlation between sMPA and total MPA and its possible contribution to MPA TDM is required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s43440-023-00474-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T21:49:57Z","timestamp":1679867397000},"page":"726-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-performance liquid chromatography with fluorescence detection for mycophenolic acid determination in saliva samples"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-1575","authenticated-orcid":false,"given":"Joanna","family":"Sobiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matylda","family":"Resztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Banasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zachwieja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Ostalska-Nowicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","volume":"43","author":"S Bergan","year":"2021","unstructured":"Bergan S, Brunet M, Hesselink DA, Johnson-Davis KL, Kunicki PK, Lemaitre F, et al. Personalized therapy for mycophenolate: consensus report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;43:150\u2013200.","journal-title":"Ther Drug Monit"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425255.2021.1843633","volume":"17","author":"R Ehren","year":"2021","unstructured":"Ehren R, Schijvens AM, Hackl A, Schreuder MF, Weber LT. Therapeutic drug monitoring of mycophenolate mofetil in pediatric patients: novel techniques and current opinion. Expert Opin Drug Metab Toxicol. 2021;17:201\u201313.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ejps.2015.06.017","volume":"77","author":"J Sobiak","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, G\u0105siorowska K, Piechanowska W, et al. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci. 2015;77:189\u201396.","journal-title":"Eur J Pharm Sci"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"\u00c1 Hackl","year":"2016","unstructured":"Hackl \u00c1, Cseprek\u00e1l O, Gessner M, Liebau MC, Habbig S, Ehren R, et al. Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit. 2016;38:274\u20139.","journal-title":"Ther Drug Monit"},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.2215\/CJN.00320116","volume":"11","author":"S Tellier","year":"2016","unstructured":"Tellier S, Dallocchio A, Guigonis V, Saint-Marcoux F, Llanas B, Ichay L, et al. Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome. Clin J Am Soc Nephrol. 2016;11:1777\u201382.","journal-title":"Clin J Am Soc Nephrol"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/00003088-200746020-00005","volume":"46","author":"H Chen","year":"2007","unstructured":"Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in chinese liver transplant recipients. Clin Pharmacokinet. 2007;46:175\u201385.","journal-title":"Clin Pharmacokinet"},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2125.2012.04305.x","volume":"75","author":"HJ Downing","year":"2013","unstructured":"Downing HJ, Pirmohamed M, Beresford MW, Smyth RL. Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol. 2013;75:45\u201359.","journal-title":"Br J Clin Pharmacol"},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/bdd.2206","volume":"40","author":"MM Alsmadi","year":"2019","unstructured":"Alsmadi MM, Alfarah MQ, Albderat J, Alsalaita G, AlMardini R, Hamadi S, et al. The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharm Drug Dispos. 2019;40:325\u201340.","journal-title":"Biopharm Drug Dispos"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00228-019-02701-5","volume":"75","author":"J Sobiak","year":"2019","unstructured":"Sobiak J, Resztak M, Pawi\u0144ski T, \u017bero P, Ostalska-Nowicka D, Zachwieja J, et al. Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study. Eur J Clin Pharmacol. 2019;75:1249\u201359.","journal-title":"Eur J Clin Pharmacol"},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/FTD.0000000000000671","volume":"41","author":"M Benz","year":"2019","unstructured":"Benz M, Ehren R, Kleinert D, M\u00fcller C, Gellermann J, Fehrenbach H, et al. Generation and validation of a limited sampling strategy to monitor mycophenolic acid exposure in children with nephrotic syndrome. Ther Drug Monit. 2019;41:696\u2013702.","journal-title":"Ther Drug Monit"},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s13318-021-00713-0","volume":"46","author":"J Sobiak","year":"2021","unstructured":"Sobiak J, Resztak M. A systematic review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration-time curve estimation. Eur J Drug Metab Pharmacokinet. 2021;46:721\u201342.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/1440-1681.13706","volume":"49","author":"J Sobiak","year":"2022","unstructured":"Sobiak J, Resztak M, Zachwieja J, Ostalska-Nowicka D. Inosine monophosphate dehydrogenase activity and mycophenolate pharmacokinetics in children with nephrotic syndrome treated with mycophenolate mofetil. Clin Exp Pharmacol Physiol. 2022;49:1197\u2013208.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1196\/annals.1384.001","volume":"1098","author":"LJ Langman","year":"2007","unstructured":"Langman LJ. The use of oral fluid for therapeutic drug management. Ann N Y Acad Sci. 2007;1098:145\u201366.","journal-title":"Ann N Y Acad Sci"},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MNH.0000000000000764","volume":"31","author":"M Beshay","year":"2022","unstructured":"Beshay M, Rhee CM, Kalantar-Zadeh K. Novel monitoring of renal function and medication levels in saliva and capillary blood of patients with kidney disease. Curr Opin Nephrol Hypertens. 2022;31:100\u20138.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s40261-019-00844-y","volume":"39","author":"E Brooks","year":"2019","unstructured":"Brooks E, Tett SE, Isbel NM, McWhinney B, Staatz CE. Investigation of the association between total and free plasma and saliva mycophenolic acid concentrations following administration of enteric-coated mycophenolate sodium in adult kidney transplant recipients. Clin Drug Investig. 2019;39:1175\u201384.","journal-title":"Clin Drug Investig"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jpba.2009.05.030","volume":"50","author":"B Shen","year":"2009","unstructured":"Shen B, Li S, Zhang Y, Yuan X, Fan Y, Liu Z, et al. Determination of total, free and saliva mycophenolic acid with a LC\u2013MS\/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal. 2009;50:515\u201321.","journal-title":"J Pharm Biomed Anal"},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1515\/CCLM.2004.248","volume":"42","author":"RE Choo","year":"2004","unstructured":"Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med. 2004;42:1273\u201387.","journal-title":"Clin Chem Lab Med"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jsps.2013.02.002","volume":"22","author":"NM Idkaidek","year":"2014","unstructured":"Idkaidek NM. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi Pharm J. 2014;22:79\u201381.","journal-title":"Saudi Pharm J"},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/01.ftd.0000211826.65607.05","volume":"28","author":"AE Mendonza","year":"2006","unstructured":"Mendonza AE, Gohh RY, Akhlaghi F. Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. Ther Drug Monit. 2006;28:402\u20136.","journal-title":"Ther Drug Monit"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"MHJ Wiesen","year":"2012","unstructured":"Wiesen MHJ, Farowski F, Feldk\u00f6tter M, Hoppe B, M\u00fcller C. Liquid chromatography\u2013tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A. 2012;1241:52\u20139.","journal-title":"J Chromatogr A"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clinbiochem.2021.11.008","volume":"100","author":"AR Cossart","year":"2022","unstructured":"Cossart AR, Staatz CE, Gorham G, Barraclough KA. Comparison of free plasma versus saliva mycophenolic acid exposure following mycophenolate mofetil administration in adult kidney transplant recipients. Clin Biochem. 2022;100:78\u201381.","journal-title":"Clin Biochem"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00228-018-02614-9","volume":"75","author":"PCL Ferreira","year":"2019","unstructured":"Ferreira PCL, Thiesen FV, de Araujo TT, D\u2019\u00c1vila DO, Gadonski G, de Oliveira CSA, et al. Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients. Eur J Clin Pharmacol. 2019;75:553\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/FTD.0b013e3181f01397","volume":"32","author":"B Chen","year":"2010","unstructured":"Chen B, Gu Z, Chen H, Zhang W, Fen X, Cai W, et al. Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. Ther Drug Monit. 2010;32:653.","journal-title":"Ther Drug Monit"},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jchromb.2007.09.036","volume":"859","author":"FA Elbarbry","year":"2007","unstructured":"Elbarbry FA, Shoker AS. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr B Anal Technol Biomed Life Sci. 2007;859:276\u201381.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"474_CR25","unstructured":"European Medicine Agency. Guideline on bioanalytical method validation 2011. http:\/\/www.ema.europa.eu\/docs\/enGB\/documentlibrary\/Scientificguideline\/2011\/08\/WC500109686.pdf. Accessed 1 Oct 2022."},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jchromb.2006.07.062","volume":"846","author":"W-P Yau","year":"2007","unstructured":"Yau W-P, Vathsala A, Lou H-X, Zhou SF, Chan E. Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2007;846:313\u20138.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"474_CR27","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/molecules27061807","volume":"27","author":"F Hameedat","year":"2022","unstructured":"Hameedat F, Hawamdeh S, Alnabulsi S, Zayed A. High performance liquid chromatography (HPLC) with fluorescence detection for quantification of steroids in clinical, pharmaceutical, and environmental samples: a review. Molecules. 2022;27:1807.","journal-title":"Molecules"},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.chroma.2012.04.008","volume":"1241","author":"MHJ Wiesen","year":"2012","unstructured":"Wiesen MHJ, Farowski F, Feldk\u00f6tter M, Hoppe B, M\u00fcller C. Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. J Chromatogr A. 2012;1241:52\u20139.","journal-title":"J Chromatogr A"},{"key":"474_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.11613\/BM.2015.018","volume":"25","author":"LAS Nunes","year":"2015","unstructured":"Nunes LAS, Mussavira S, Bindhu OS. Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review. Biochem Med. 2015;25:177\u201392.","journal-title":"Biochem Med"},{"key":"474_CR30","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/v12070735","volume":"12","author":"B Pastorino","year":"2020","unstructured":"Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics? Viruses. 2020;12:735.","journal-title":"Viruses"},{"key":"474_CR31","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/infdis\/jiaa507","volume":"222","author":"EI Patterson","year":"2020","unstructured":"Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-Utrilla C, et al. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J Infect Dis. 2020;222:1462\u20137.","journal-title":"J Infect Dis"},{"key":"474_CR32","doi-asserted-by":"publisher","first-page":"9434","DOI":"10.1038\/s41598-022-13491-9","volume":"12","author":"E Lamy","year":"2022","unstructured":"Lamy E, Rubio CP, Carreira L, Capela E, Silva F, Martinez-Subiela S, Tecles F, et al. Effect\n of thermal and chemical treatments used for SARS-COV-2 inactivation in the measurement of saliva analytes. Sci Rep. 2022;12:9434.","journal-title":"Sci Rep"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00474-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-023-00474-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00474-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T03:40:01Z","timestamp":1685418001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-023-00474-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s43440-023-00474-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"In the studies involving human participants all procedures were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee at Poznan University of Medical Sciences (Decisions No.: 773\/21 of 06.10.2021 and 808\/22 of 06.10.2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to participate was obtained from all parents or guardians of individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}